CCHT(SZ:000661) Ge Long Hui·2026-01-15 09:40Core Viewpoint - The company has received a significant upfront payment of $70 million from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, which is set to undergo clinical trials for thyroid-related eye disease and Graves' disease in China and the United States [1] Group 1 - The company’s subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology Co., Ltd., which is involved in the licensing agreement [1] - The GenSci098 injection has been approved to commence clinical trials for thyroid eye disease (TED) in both mainland China and the United States starting August 2024 [1] - The injection is also set to be approved for clinical trials for Graves' disease (GD) in mainland China by October 2025 [1]